Ratings Bayer CropScience Limited

Equities

BAYERCROP

INE462A01022

Market Closed - Bombay S.E. Other stock markets 03:00:39 2024-05-18 am EDT			5-day change	1st Jan Change
5,582 ^INR	0.00%		+6.86%	+0.87%

Feb. 01	Bayer CropScience Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	India's Bayer Cropscience post jump in Q2 profit as rainfall recovery aids demand	RE

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The group's high margin levels account for strong profits.
The company is in a robust financial situation considering its net cash and margin position.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.41 times its estimated earnings per share for the ongoing year.
The company's enterprise value to sales, at 4.45 times its current sales, is high.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Agricultural Chemicals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
BAYER CROPSCIENCE LIMITED	+0.87%	3.01B		C+
CORTEVA, INC.	+18.41%	39.34B		C
PHOSAGRO	-.--%	11.28B	-	B+
FMC CORPORATION	+1.30%	7.99B		A
PI INDUSTRIES LIMITED	+1.79%	6.51B		B-
ICL GROUP LTD	-4.79%	6.02B		B+
OCI N.V.	-1.37%	5.85B		B
YUNNAN YUNTIANHUA CO., LTD.	+40.90%	5.43B		B-
THE FERTILISERS AND CHEMICALS TRAVANCORE LIMITED	-13.59%	5.41B	-	C-
UPL LIMITED	-13.00%	4.61B		C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders